Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

Speciality: Oncology

Description:

A warm welcome to all the medical professionals in this exciting learning session on the frontline management of ALK rearranged non-small cell lung cancer with lorlatinib.

The ALK gene encodes a transmembrane tyrosine kinase receptor which is expressed physiologically during embryogenesis and its expression decreases postnatally. The rearrangements of ALK were first identified in 2007 in NSCLC, and it is observed that the 3′ region of the ALK gene gets fused with the 5′ sequence of the echinoderm microtubule-associated protein-like 4 (EML4) gene. This rearrangement results in the expression of the EML4-ALK fusion protein. 

This EML4–ALK proteins are highly transforming and pathogenic. In case of NSCLC an increase in oligomerization and constitutive, kinase-activating autophosphorylation is observed involving several signaling pathways such as RAS/MAP kinase and others which leads to cell proliferation and de-differentiation.

Lorlatinib can be used in such cases as the clinical trials have shown the robust systemic and intracranial anti-tumor activity of lorlatinib in ALK rearranged advanced NSCLC. Moreover, the adverse events of the drug are also unique and manageable.

Therefore, listen to the webinar, grab the shared knowledge, and follow HiDoc for more such interesting webinar sessions.

See More Webinars @ Hidoc Webinars